CAS: 1186486-62-3; 4-Trans-(((S)-5-((3,5-Bis(Trifluoromethyl)Benzyl)(2-Methyl-2H-Tetrazol-5-yl)Amino)-7,9-Dimethyl-2,3,4,5-Tetrahydro-1H-Benzo[b]Azepin-1-yl)Methyl)Cyclohexanecarboxylic Acid

该化合物是一个小分子,它作为酶胆固醇转移蛋白的选择性抑制剂(CETP)作用.该化合物主要通过调制脂肪剖面,特别是通过提高高密度脂质(HDL)胆固醇水平,同时降低低密度脂蛋白(LDL)胆固醇水平,来调查其在治疗痢疾和心血管疾病方面的潜力.Evacestrapib的特点是其特定的化学结构,其中包括有助于其生物活动和选择性的各种功能组.该化合物经历了各种临床试验,以评估其功效和安全性,特别是心血管结果.其药性动力特性,如吸收,分布,代谢和排泄,对于确定其治疗潜力和剂量疗法至关重要.

结构式图片

欧盟法规

ECHA物质C&L通报

合成工艺路线路线简述

    📜(1R,4R)-Methyl 4-((5-((3,5-Bis(Trifluoromethyl)Benzyl)(2-Methyl-2H-Tetrazol-5-yl)Amino)-7,9-Dimethyl-2,3,4,5-Tetrahydro-1H-Benzo[b]Azepin-1-yl)Methyl)Cyclohexanecarboxylate置于水,Sodium Hydroxide体系中,用 异丙醇 用作溶剂,化学反应 7.0H,反应生成反式-4-[[(5S)-5-[[[3,5-双(三氟甲基)苯基]甲基](2-甲基-2H-四氮唑-5-基)氨基]-2,3,4,5-四氢-7,9-二甲基-1H-1-苯并氮杂卓-1-基]甲基]环己烷羧酸,(1R,4S)-4-(((S)-5-((3,5-Bis(Trifluoromethyl)Benzyl)(2-Methyl-2H-Tetrazol-5-yl)Amino)-7,9-Dimethyl-2,3,4,5-Tetrahydro-1H-Benzo[b]Azepin-1-yl)Methyl)Cyclohexane-1-Carboxylic Acid
    参考文献:Development Of A Hydrogenative Reductive Amination For The Synthesis Of Evacetrapib: Unexpected Benefits Of Water
    标题:Development Of A Hydrogenative Reductive Amination For The Synthesis Of Evacetrapib: Unexpected Benefits Of Water
    摘要:For The Synthesis Of Cholesteryl Ester Transfer Protein (Cetp) Inhibitor Evacetrapib,A Hydrogenative Reductive Amination Was Chosen To Join The Substituted Cyclohexyl Subunit To The Benzazepine Core. The Addition Of Water,Which Suppressed Undesired Epimerization Without Affecting The Rate Of Product Formation,Was Key To The Reaction'S Success. The Process Was Scaled To Produce More Than 1100 Kg Of Material.
    Doi:10.1021/op500025V

    专利信息


    专利号:CN-107098946-A
    优先权日:2016-02-23
    标题:Synthesis and Application of CETP Inhibitors

    专利号:CN-107098946-B
    优先权日:2016-02-23
    标 题:Synthesis and Application of CETP Inhibitors

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Nicholls SJ. Evacetrapib. Curr Cardiol Rep. 2012 Jun;14(3):245-50. doi: 10.1007/s11886-012-0252-3. 25(2):43-52. doi: 10.1097/CRD.0000000000000137.
    14:1171937. doi: 10.3389/fphar.2023.1171937.
    4: Sahebkar A, Simental-Mendía LE, Guerrero-Romero F, Golledge J, Watts GF. Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr Pharm Des. 2016;22(5):595-608. doi: 10.2174/1381612822666151125000035. ACCELERATE Investigators. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581. 9(8):2308-2310. doi: 10.21037/jtd.2017.07.75.

    合成参考文献


    参考文献:10.1007/s40262-018-0656-3
    摘要:Black DM, Bentley D, Chapel S, Lee J, Briggs E, Heinonen T. Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib. Clinical Pharmacokinetics. 2018 May 05;57(11):1359–67. doi: 10.1007/s40262-018-0656-3.
    参考文献:10.1007/s11936-019-0741-4
    摘要:Jones-O’Connor M, Natarajan P. Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. Current Treatment Options in Cardiovascular Medicine. 2019 Jun 29;21(8):38. doi: 10.1007/s11936-019-0741-4.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知